FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
HM43239 Sensitive: B - Late Trials
Aptose Biosci Press Release - 3 weeks (NewB)
|
HM43239 Sensitive: B - Late Trials
Aptose Biosci Press Release - 3 weeks - (New B)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
gilteritinib Sensitive: A1 - Approval
|
gilteritinib Sensitive: A1 - Approval
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
midostaurin Sensitive: A1 - Approval
|
midostaurin Sensitive: A1 - Approval
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
FLT3 inhibitor Sensitive: B - Late Trials
|
FLT3 inhibitor Sensitive: B - Late Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax + azacitidine Sensitive: B - Late Trials
|
venetoclax + azacitidine Sensitive: B - Late Trials
|
FLT3 mutation
|
Leukemia
|
FLT3 mutation
|
Leukemia
|
midostaurin Sensitive: B - Late Trials
|
midostaurin Sensitive: B - Late Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria
|
quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria
|
Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
CEP-701 Sensitive: C2 – Inclusion Criteria
|
CEP-701 Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
ARO-002 Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
sorafenib Sensitive: C2 – Inclusion Criteria
|
sorafenib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria
|
FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax + midostaurin Sensitive: C3 – Early Trials
|
venetoclax + midostaurin Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax + sorafenib Sensitive: C3 – Early Trials
|
venetoclax + sorafenib Sensitive: C3 – Early Trials
|
FLT3 mutation
|
NSCLC
|
FLT3 mutation
|
NSCLC
|
nintedanib Sensitive: C3 – Early Trials
|
nintedanib Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
ivosidenib Resistant: C3 – Early Trials
|
ivosidenib Resistant: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials
|
FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials
|
midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies
|
cytarabine / daunorubicin liposomal formulation Sensitive: C4 – Case Studies
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
MEK inhibitor + FLT3 inhibitor Sensitive: D – Preclinical
|
MEK inhibitor + FLT3 inhibitor Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
sorafenib + LY3009120 Sensitive: D – Preclinical
|
sorafenib + LY3009120 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
PF-02545920 Sensitive: D – Preclinical
|
PF-02545920 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
5-fluorouracil Sensitive: D – Preclinical
|
5-fluorouracil Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
quizartinib + IACS-010759 Sensitive: D – Preclinical
|
quizartinib + IACS-010759 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
AG-1296 Sensitive: D – Preclinical
|
AG-1296 Sensitive: D – Preclinical
|
FLT3 mutation
|
CML
|
FLT3 mutation
|
CML
|
sunitinib Sensitive: D – Preclinical
|
sunitinib Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
SU5614 Sensitive: D – Preclinical
|
SU5614 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
ASP7487 + NT-157 Sensitive: D – Preclinical
|
ASP7487 + NT-157 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
venetoclax + olaparib Sensitive: D – Preclinical
|
venetoclax + olaparib Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
OTS167 Sensitive: D – Preclinical
|
OTS167 Sensitive: D – Preclinical
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
gilteritinib + ERAS-601 Sensitive: D – Preclinical
|
gilteritinib + ERAS-601 Sensitive: D – Preclinical
|